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Phase II Trials -endpoints, when to randomize Zee, Benny Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China The primary objective of phase II trials is to screen a new agent or regimen for efficacy and to provide estimates of its level of activity. In this workshop we will discuss commonly used endpoints such as complete plus partial response rate (overall response rate) and their corresponding analysis and interpretation. The use of multiple-stage design to minimize increase the efficiency of screening will be discussed. The importance in the design of phase II trials to minimize the chance that a truly active agent is erroneously rejected will also be discussed. There are circumstances that randomized phase II trial may be appropriate and its correct interpretation will be discussed.
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Designs with targeted therapies
West, Howard Swedish Cancer Institute, Seattle, WA, USA The study of targeted therapies in oncology requires consideration of several features that are unique to this class of agents. Trials of molecularly targeted therapies need to carefully assess whether it is appropriate to restrict the study of a targeted therapy to a population with a molecular variable that may be particularly relevant to a targeted therapy, or whether it is more appropriate to open the trial to a broader population that may experience a less consistent and robust improvement in clinical endpoints. Designs of trials with targeted therapies may also need to redefine the importance of such endpoints as maximum tolerated dose versus minimal effective dose, and of objective response versus disease control/non-progression. Trials designed as a "window of opportunity" allow for the rapid testing of a targeted therapy with a biological endpoint, while other trials with this design may incorporate novel endpoints such as metabolic imaging to assess results rapidly. Examples of clinical trials with targeted therapies in lung cancer also illustrate how early use of combinations of conventional chemotherapy and targeted therapy may obfuscate the contribution of the molecular therapy or may even produce antagonistic combinations, and of how a cross-over design may introduce new challenges in the interpretation of the contribution of a novel targeted therapy. Finally, multi-targeted single agents and combinations of different targeted therapies raise additional questions in clinical trial design of how to optimize efficacy, minimize safety risks, and evaluate the clinical benefit of regimens compared with traditional standards using more conventional agents.
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Novel clinical trial design applying Bayesian adaptive randomization for targeted therapy in lung cancer -A step toward personalized medicine
Lee, J. Jack Department of Biostatistics, M. D. Anderson Cancer Center, Houston, TX, USA Background: With the advancement in the understanding of multiple signaling pathways associated with lung cancer, many targeted therapies have been developed. Utilization of molecularly targeted agents can inhibit these specific aberrant pathways, hence, lead to clinical efficacy. The targeted agents, however, may not work for everyone. Biomarkers expressions can be used as indicators for the aberrant signaling to identify effective targeted therapy. Our major goals are to characterize the molecular signature of individual tumors, to offer bestfit targeted therapy to patients on the trial, and to identify promising targeted agents for future development.
Methods:
We have developed the "BATTLE" program, "Biomarkerintegrated Approaches of Targeted Therapy of Lung Cancer Elimination," which consists of an umbrella screening trial and 4 parallel phase II targeted therapies trials (with erlotinib, sorafenib, vandetanib, and the combination of erlotinib and bexarotene) in advanced non-small cell lung cancer patients with prior chemotherapy. All patients will have biopsy samples taken for biomarker profile assessment prior to the randomization, then they will be classified into one of the five marker groups: 1) EGFR mutation/amplification, 2) K-ras and/or B-raf mutation, 3) VEGF and/or VEGFR expression, 4) RXR and/or cyclin
